Savara announced the appointment of Braden Parker as chief commercial officer, effective immediately. Parker is responsible for overseeing Savara’s global commercial strategy for molgramostim inhalation solution in autoimmune Pulmonary Alveolar Proteinosis, or aPAP. Parker joins Savara from Orchard Therapeutics, where he served as chief commercial officer.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA: